4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-052227
Chief Accounting Officer sold 222 shares at $1.98 ($439)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hagen Brett R · Chief Accounting Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-10-03 | Sale : show line 1 in the form 10b5-1 | −222 | $1.98 | $439 | 126,953 | D |
| Open-market sales · 222 sh · avg $1.98 · $439 | ||||||
Loading xslF345X05/doc4.xml…